|
Dibenzyl (carbonylbis{2,1-hydrazinediyl[(2S)-4-methyl-1-oxo-1,2-pentanediyl]})biscarbamate
|
DB03891 |
|
|
[(1S)-1-acetamido-2-(4-chlorophenyl)ethyl]-[(2S)-2-amino-3-hydroxy-3-oxo-propoxy]-dihydroxy-boron
|
DB02560 |
|
|
Fentiazac
|
DB13217 |
|
|
Gallium cation Ga-67
|
DB14549 |
|
|
Zinc sulfate, unspecified form
|
DB14548 |
|
|
Mandelic acid
|
DB13218 |
[Mandelic acid is an approved aromatic, alpha hydroxy acid [L5458]. Mandelic acid is used as an ingredient in cosmetics and drug products applied topically.] |
|
Medifoxamine
|
DB13219 |
[Medifoxamine was marketed as an atypical antidepressant, with anxiolyitc properties in France, Spain, and Morrocco in the 1990s but was later withdrawn from the market due to it causing cases of hepatotoxicity [L5461, A174976].] |
|
Butaperazine
|
DB13213 |
[Butaperazine was approved in 1967 [L5143], and possibly discontinued in the 1980s [T397].] |
|
Hydrocortisone succinate
|
DB14545 |
|
|
Hydrocortisone valerate
|
DB14544 |
|
|
Sulfadicramide
|
DB13214 |
|
|
Chloride ion
|
DB14547 |
|
|
Sulfobromophthalein
|
DB13215 |
[Sulfobromophthalein or otherwise called bromsulphthalein is used as a test of liver function in humans [A174970].] |
|
Oxolamine
|
DB13216 |
[Oxolamine is not approved in the USA, it may be marketed elsewhere internationally as a cough suppressant [L5416]. It is listed as a prescription drug in New Zealand legislation [L5419]. Oxolamine is also approved in Taiwan for the treatment of respiratory tract inflamation [L5422].] |
|
Sulfate ion
|
DB14546 |
|
|
Hydrocortisone cypionate
|
DB14541 |
|
|
Hydrocortisone butyrate
|
DB14540 |
|
|
Sodium chlorite
|
DB13210 |
[Used as an agent for cleaning drinking water. It is also used as an additive in products like toothpaste and mouthwash. Acidified sodium chlorite was approved by the U.S. Food and Drug Administration as of 2004, as an anti-microbial agent which is non-toxic, but not as a drug [A174811, L5413].] |
|
Hydrocortisone probutate
|
DB14543 |
|
|
Guanoxan
|
DB13211 |
[Guanoxan is an antihypertensive agent similar in its mechanism of action to guanethidine; may cause liver damage.
Guanoxan was approved in the UK but was withdrawn from the market due to hepatotoxicity.] |